The research team, led by investigators affiliated with Tanta University and collaborating institutions in Egypt and Afghanistan, systematically searched six major databases—PubMed, the Cochrane Library, Scopus, Web of Science, ScienceDirect, and Embase—from their inception through September 19, 2025. The search captured phase I through phase III clinical trials as well as prospective interventional studies evaluating any replication-competent oncolytic herpes simplex virus agent in adults aged 18 or older with solid tumors. The review was prospectively registered with PROSPERO under registration number CRD420261279371 and conducted in accordance with the PRISMA 2020 reporting guidelines, lending methodological rigor to an analysis that spans a technically diverse and rapidly evolving therapeutic modality.

The headline numbers are grounded in sophisticated statistical machinery. The pooled objective response rate—the proportion of patients whose tumors measurably shrank—across 33 studies encompassing 1,409 patients was 29.6 percent, with a 95 percent confidence interval of 23.5 to 36.6 percent. Disease control, a broader measure that also captures patients whose tumors stabilized, reached 55.8 percent across 21 studies including 699 patients, with a confidence interval stretching from 42.8 to 68.1 percent. These estimates were computed using a DerSimonian-Laird random-effects model with Freeman-Tukey double arcsine transformation, a technique well suited to proportions, and the primary outcomes were refined with Hartung-Knapp adjustment to better account for uncertainty when the number of studies is limited. Prediction intervals were reported alongside confidence intervals, giving clinicians a more honest sense of the range of outcomes a future patient population might plausibly experience.

Notably, the authors did not shy away from the heterogeneity that pervades the field. The I-squared statistic, a standard measure of the proportion of variation across studies attributable to real differences rather than chance, reached 74.6 percent for objective response and 81.1 percent for disease control—figures that signal substantial variability across tumor types, viral constructs, dosing regimens, and patient populations. Such heterogeneity is almost inevitable in a literature that spans different engineered viruses, delivery routes, and cancers, but it also means that the pooled estimates should be read as a survey of a landscape rather than a single prescription. Subgroup analyses pre-specified by cancer type and virus type were designed precisely to begin untangling these threads, and the results point clearly toward where oncolytic herpes virus therapy has gained the firmest footing.

That firmest footing is on the skin. Skin cancers demonstrated the highest response rates in the entire dataset, with an objective response rate of 55.6 percent, although the authors candidly note this estimate derives from a single study and must therefore be interpreted with caution. Still, it aligns with the broader consensus that has accumulated since T-VEC—technically, talimogene laherparepvec—won regulatory approval for advanced melanoma. The analysis concludes that the strongest evidence supports the use of T-VEC in injectable melanoma and other skin cancers, where direct intratumoral injection allows the virus to encounter accessible tumor deposits and where melanoma’s inherent immunogenicity may amplify the viral immune stimulation. In contrast, the authors explicitly caution that findings in breast, colorectal, pancreatic, and other non-melanoma tumors should be considered hypothesis-generating rather than practice-changing, requiring confirmation in larger, cancer-type-specific trials before any broader adoption can be justified.

Survival outcomes painted a picture of incremental but meaningful benefit. The pooled 12-month overall survival rate was 69.6 percent, with a confidence interval of 60.7 to 77.3 percent, while the 24-month rate was 52.6 percent, ranging from 44.5 to 60.6 percent. For a class of experimental agents frequently tested in heavily pretreated, advanced-stage patients—populations in which standard options have often been exhausted—these figures suggest that a meaningful fraction of patients live well beyond the first year after treatment. The heterogeneity in survival data, with I-squared values of 78.0 and 72.2 percent respectively, again reflects the diversity of the underlying trials, but the direction of the signal is consistent with the immunotherapeutic premise: viral lysis of tumor cells releases antigens that can prime durable systemic immune responses.

Safety is often the decisive question for any viral therapy, and here the meta-analysis offers both reassurance and nuance. Treatment-related adverse events of any grade occurred in 86.3 percent of patients, with a confidence interval of 70.8 to 94.2 percent—hardly surprising, since these are live, replicating viruses. The most common events were pyrexia, reported in 46.9 percent of the 1,304 patients across all 38 studies, and chills, affecting 34.0 percent, both classic hallmarks of the systemic immune activation that these viruses are engineered to provoke. More clinically consequential grade 3 to 5 events occurred in 20.5 percent of patients, with a confidence interval of 13.6 to 29.6 percent. Crucially, treatment-related mortality was low at 2.5 percent, with a tight confidence interval of 1.6 to 4.0 percent and, remarkably, no heterogeneity—an I-squared of 0 percent—suggesting this figure was consistent across the entire evidence base.

The authors subjected their findings to an unusually thorough robustness battery. Sensitivity analyses confirmed the stability of the pooled estimates, but tests for publication bias told a more guarded story. Egger’s test, trim-and-fill analysis, and contour-enhanced funnel plots detected evidence of publication bias for both disease control rates and any treatment-related adverse events, meaning that smaller studies reporting favorable results may be overrepresented in the published literature. This is a common challenge in meta-analyses of early-phase oncology trials, where negative or preliminary findings are less likely to reach print, and it underscores that the pooled figures—particularly for disease control—should be viewed as upper-bound estimates of real-world effect. The high heterogeneity figures reinforce the same message: the field needs optimized viral backbones and biomarker-driven patient selection to convert promise into precision.

What emerges from the analysis is neither a triumphalist nor a dismissive verdict, but something more useful: a calibrated map of where engineered herpes viruses have earned their place in the oncology armamentarium and where they have not yet done so. Oncolytic herpes simplex virus therapy, the data suggest, is a versatile immunotherapy platform with modest average anti-tumor activity that is highly context-dependent—exceptional in injectable skin cancers, still speculative in visceral malignancies. As next-generation constructs with enhanced selectivity, immune-modulating transgenes, and systemic delivery strategies move through the clinic, the benchmark established by this meta-analysis—roughly one in three patients achieving objective response, disease control in more than half, and treatment-related death below 3 percent—will serve as the standard against which the next generation of tumor-killing viruses must prove themselves.

Subject of Research: Oncolytic herpes simplex virus therapy for solid tumors

Article Title: Efficacy and safety of oncolytic herpes simplex virus therapy in solid tumors: a systematic review and meta-analysis of 38 clinical trials

Article References: Abady, E., Abdelbaqi, H., Mohamed, E. S. A., Abdelsater, A. A., Hassan, A., Hesham, Y., Youssef, A. A., Khaled, H., Soliman, R., Sadaqat, A., & Masoud, H. F. A. (2026). Efficacy and safety of oncolytic herpes simplex virus therapy in solid tumors: a systematic review and meta-analysis of 38 clinical trials. BMC Cancer. https://doi.org/10.1186/s12885-026-16739-z

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16739-z

Keywords: oncolytic herpes simplex virus, oHSV, T-VEC, talimogene laherparepvec, solid tumors, melanoma, immunotherapy, meta-analysis, systematic review, clinical trials, cancer therapy, oncolytic virotherapy

The authors ground their argument in a fundamental limitation shared by immune checkpoint inhibitors and early-generation oncolytic viruses alike: both depend on pre-existing tumor-specific T cells to work. Checkpoint blockade releases the brakes on T cells that already recognize cancer, but it has little capacity to generate new tumor-reactive clones de novo. Similarly, first-generation OVs were designed primarily to replicate in and destroy tumor cells, releasing antigens in the hope that an antitumor response would follow. If a patient’s immune system has not already been sensitized to their cancer, the ceiling on efficacy is set by the existing T cell repertoire, an immunological constraint that clinical experience has repeatedly confirmed. Resistance rates for checkpoint inhibitors across tumor types remain substantial, and even approved OVs have produced durable responses mainly in a subset of patients.

The central conceptual advance proposed in the Perspective is that next-generation OVs overcome this ceiling by functioning as antigen-agnostic, in situ cancer vaccines. When an oncolytic virus infects a tumor, it triggers immunogenic cell death, a form of tumor destruction that releases not just one or two chosen antigens but potentially the full cancer proteome, all under adjuvant conditions created by pathogen-associated and damage-associated molecular patterns. Dendritic cells patrolling the inflamed tumor microenvironment engulf this debris and migrate to draining lymph nodes, where they present the entire antigenic spectrum of that patient’s cancer, including private neoantigens arising from mutations unique to the tumor. This process can broaden the T cell clonotype repertoire, effectively priming brand-new tumor-specific T cells rather than merely reactivating exhausted ones. In essence, each treated tumor becomes its own personalized vaccine factory, without needing to sequence a patient’s genome or manufacture an individualized product.

The authors organize the path forward around four pillars. The first is intratumoural vaccination as immunological ignition. They cite early clinical data demonstrating T cell clonotype broadening, regression of uninjected, so-called abscopal lesions, and survival benefit in patients whose disease had already failed checkpoint inhibitor therapy. These signals matter because abscopal responses, long considered rare curiosities of radiotherapy and immunotherapy, provide direct evidence that a locally delivered virus can reprogram immunity systemically. The second pillar is optimized, payload-driven immune priming. Modern OVs are increasingly engineered to carry transgenes encoding cytokines such as granulocyte-macrophage colony-stimulating factor, interleukin-12 and interleukin-15, or antibodies and nanobodies that block checkpoint pathways or hyperactivate antigen-presenting cells. The design goal is to convert the natural viral danger signals into a maximally productive priming event for dendritic cells and, through them, for naive T cells.

The third pillar addresses a quieter crisis in the field: how efficacy is measured. Standard RECIST criteria, which track the shrinkage of injected and measurable lesions, can systematically underestimate the delayed, nonlinear kinetics of immune-mediated tumor control. The authors call for revised evaluation frameworks incorporating immune-specific response criteria such as iRECIST, attention to durable response rates, and novel biological correlates such as circulating tumor DNA dynamics and T cell receptor repertoire diversification. Evidence already suggests that for some immunotherapies, including oncolytic agents, apparent stable disease can conceal a durable immune equilibrium that translates into extended overall survival even without dramatic radiographic regression. Regulatory acceptance of endpoints that capture these patterns will be essential if next-generation OVs are to reach patients.

The fourth and most ambitious pillar is the positioning of OVs as the foundational immuno-oncology platform, formalized in what the authors call the triple-A framework. Productive antitumor immunity requires three sequential gates: admission of T cells into the tumor, their availability in sufficient numbers with appropriate specificity, and their activation to effector function. Most therapeutic modalities satisfy only one or two of these conditions. Checkpoint inhibitors excel at activation but assume T cells are already present and tumor-specific. Adoptive cell therapies and bispecific T cell engagers supply availability and activation but struggle with physical admission into immunosuppressed, poorly vascularized tumor stroma. Payload-engineered next-generation OVs, the authors argue, are unique in satisfying all three prerequisites simultaneously: viral infection remodels the microenvironment to admit T cells, in situ vaccination generates and expands tumor-specific clones to ensure availability, and inflammatory danger signals plus engineered payloads drive activation.

The clinical landscape they survey is evolving rapidly. Talimogene laherparepvec, the first approved oncolytic virus in the United States, established proof of principle in melanoma, and combination trials with pembrolizumab and ipilimumab have tested whether viral priming can amplify checkpoint blockade. A strategy the authors describe as OV-prime, ICI-amplify is supported by trial data showing that vaccinating the immune system with a virus first and then removing inhibitory brakes with an antibody can yield benefit even in patients refractory to checkpoints alone. Newer agents illustrate the payload engineering trend: RP1, an oncolytic herpesvirus expressing GM-CSF and a fusogenic protein, has shown activity with nivolumab in anti-PD-1-failed melanoma and recently gained support from a US Food and Drug Administration advisory committee. In China, VG161, a multi-armoured oncolytic herpesvirus carrying multiple immunomodulatory transgenes, has demonstrated survival benefits in refractory hepatocellular carcinoma, while T3011, an oncolytic herpesvirus expressing both interleukin-12 and a PD-1 antibody, has entered first-in-human testing in advanced solid tumors.

Delivery logistics remain a genuine constraint that the authors confront directly. Most OVs are administered by intratumoral injection, which is straightforward for accessible cutaneous lesions but demanding for deep visceral metastases, although ultrasound-guided techniques are expanding the reachable set. Intravenous delivery, which would extend the approach to diffuse disease, is hampered by neutralizing antibodies, hepatic clearance and off-target sequestration, prompting engineering solutions ranging from cell carriage by mesenchymal stem cells and immune cells to polymer coating and tumor-specific promoter control of viral replication. Pre-existing antiviral immunity, once viewed purely as a barrier, may in some contexts enhance rather than diminish therapeutic efficacy by amplifying inflammatory recruitment to infected tumors. None of these obstacles is trivial, but the Perspective treats them as engineering problems rather than conceptual dead ends.

The broader significance of the argument lies in its reframing of therapeutic sequencing. If oncolytic viruses are truly systemic immune-reprogramming platforms, then the optimal role for an OV in a treatment regimen may be as the priming event, the ignition that creates the tumor-specific T cell pool, with checkpoint inhibitors, bispecifics or adoptive cells deployed afterwards to amplify and sustain the response. The authors acknowledge competing interests that come with their positions in oncolytic virotherapy companies, and the piece is explicitly a Perspective rather than a definitive clinical mandate. Still, the case they assemble, spanning mechanistic immunology, evolving trial data and a coherent framework for combination design, makes a credible argument that the field’s future lies not in making cold tumors hot, but in teaching the immune system, one infected tumor at a time, to recognize cancers it had never seen.

Historical context reinforces the authors’ argument that the field has been converging on this reframing for decades. The conceptual roots of oncolytic virotherapy stretch back more than a century to anecdotal reports of tumor regression after natural viral infections, but the modern era began in the early 1990s when Robert Martuza’s group described a genetically engineered herpes simplex virus mutant that could replicate in and destroy glioma cells. Landmark studies in the late 1990s and early 2000s established the tumor-selective logic of the field, exploiting activated ras signaling pathways, p53-deficient tumor cells, and defective interferon responses that characterize many cancers. Notably, the in situ vaccination concept itself was articulated in preclinical work as early as 1998, when replication-competent herpesviruses engineered to carry interleukin-12 were shown to induce local and systemic antitumor immunity, suggesting the current Perspective formalizes ideas whose time has finally arrived with enabling payload technology.

Safety data also support the platform’s maturation. Systematic reviews and meta-analyses of oncolytic virotherapy across malignancies have generally found favorable tolerability profiles, with most adverse events consisting of transient fever, injection-site reactions, and flu-like symptoms rather than the immune-related toxicities that complicate checkpoint blockade. This tolerability is clinically meaningful because it permits rational combination with other immunotherapies without prohibitive overlapping toxicity, a persistent challenge in immuno-oncology. At the same time, the empirical analysis of checkpoint inhibitor eligibility and response rates cited by the authors underscores the scale of unmet need: only a minority of patients who receive checkpoint inhibitors derive durable benefit, leaving a large population for whom antigen-agnostic priming strategies could be decisive. Whether the four-pillar framework translates into regulatory endorsements and standardized endpoints will likely determine how quickly next-generation oncolytic viruses move from promising biology to established cornerstone of cancer care.

Subject of Research: Next-generation oncolytic virotherapy as antigen-agnostic in situ cancer vaccination and a foundational immuno-oncology platform

Article Title: Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology

Article References: Jia, W., Zhao, R., Kaufman, H. L., & Martuza, R. L. (2026). Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-026-01198-z

Image Credits: AI Generated

DOI: 10.1038/s41571-026-01198-z

Keywords: oncolytic virotherapy, immuno-oncology, immune checkpoint inhibitors, in situ cancer vaccination, tumor-specific T cells, immunogenic cell death, abscopal response, neoantigens, talimogene laherparepvec, dendritic cells, triple-A framework, cancer immunotherapy